209 related articles for article (PubMed ID: 22851038)
1. Keratin expression in breast cancers.
Shao MM; Chan SK; Yu AM; Lam CC; Tsang JY; Lui PC; Law BK; Tan PH; Tse GM
Virchows Arch; 2012 Sep; 461(3):313-22. PubMed ID: 22851038
[TBL] [Abstract][Full Text] [Related]
2. Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases.
Tot T
Ann Diagn Pathol; 1999 Dec; 3(6):350-6. PubMed ID: 10594286
[TBL] [Abstract][Full Text] [Related]
3. The cytokeratin profile of medullary carcinoma of the breast.
Tot T
Histopathology; 2000 Aug; 37(2):175-81. PubMed ID: 10931242
[TBL] [Abstract][Full Text] [Related]
4. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: I. Cytokeratin profile in 42 cases.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):703-10. PubMed ID: 23573317
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin profiles of male breast cancers.
Ciocca V; Bombonati A; Gatalica Z; Di Pasquale M; Milos A; Ruiz-Orrico A; Dreher D; Folch N; Monzon F; Santeusanio G; Perou CM; Bernard PS; Palazzo JP
Histopathology; 2006 Oct; 49(4):365-70. PubMed ID: 16978199
[TBL] [Abstract][Full Text] [Related]
9. Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters.
Chen MH; Yip GW; Tse GM; Moriya T; Lui PC; Zin ML; Bay BH; Tan PH
Mod Pathol; 2008 Oct; 21(10):1183-91. PubMed ID: 18536655
[TBL] [Abstract][Full Text] [Related]
10. Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma.
Patel NA; Patel PS; Vora HH
Breast Dis; 2015; 35(2):113-27. PubMed ID: 25547164
[TBL] [Abstract][Full Text] [Related]
11. Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer.
Wang X; Zhong W; Bu J; Li Y; Li R; Nie R; Xiao C; Ma K; Huang X; Li Y
Mol Carcinog; 2019 May; 58(5):674-685. PubMed ID: 30604894
[TBL] [Abstract][Full Text] [Related]
12. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and "triple-negative" breast cancers.
Wang X; Chao L; Li X; Ma G; Chen L; Zang Y; Zhou G
Hum Pathol; 2010 Mar; 41(3):401-6. PubMed ID: 19913278
[TBL] [Abstract][Full Text] [Related]
14. Expression of metalloproteases and their inhibitors in different histological types of breast cancer.
Del Casar JM; González-Reyes S; González LO; González JM; Junquera S; Bongera M; García MF; Andicoechea A; Serra C; Vizoso FJ
J Cancer Res Clin Oncol; 2010 Jun; 136(6):811-9. PubMed ID: 19916023
[TBL] [Abstract][Full Text] [Related]
15. Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma.
Yamagishi H; Imai Y; Okamura T; Fukuda K; Ono Y; Ban S; Inoue T; Ueda Y
J Gastroenterol Hepatol; 2013 Dec; 28(12):1815-22. PubMed ID: 23808938
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
17. St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
Falck AK; Röme A; Fernö M; Olsson H; Chebil G; Bendahl PO; Rydén L
Br J Surg; 2016 Apr; 103(5):513-23. PubMed ID: 26856820
[TBL] [Abstract][Full Text] [Related]
18. Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast.
Chu JS; Chang KJ
Cancer Lett; 1999 Jul; 142(1):121-7. PubMed ID: 10424790
[TBL] [Abstract][Full Text] [Related]
19. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
20. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.
Delgallo WD; Rodrigues JR; Bueno SP; Viero RM; Soares CT
Cytopathology; 2010 Aug; 21(4):259-66. PubMed ID: 19843143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
